Patients who were assigned to an axitinib containing treatment arm in a previous clinical trial
Patients who were receiving axitinib tablets at the time their previous trial ended
Patients who have stable (SD) or responding disease (PR or CR) documented by the appropriate radiological, clinical, or laboratory assessments within 12 weeks before enrollment (Note: response criteria from the previous AG-013736 protocol should be used to determine stable or responding disease).
Patients who have progressive disease (PD) but have experienced "clinical benefit" as defined in the study protocol
You CAN'T join if...
Patients may not participate in this trial if the conditions for continuing treatment in the previous AG-013736 protocol are not met
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, 94158, United States
UCLA Hematology-Oncology-Santa Monica Santa Monica, California, 90404, United States
UC Irvine Medical Center Orange, California, 92868, United States
University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center Orange, California, 92868, United States